Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial

[1]  P. Valensi,et al.  Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension , 2022, Cardiovascular Diabetology.

[2]  K. Node,et al.  Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents , 2021, Cardiovascular Diabetology.

[3]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[4]  M. Packer.  Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes. , 2021, JACC. Heart failure.

[5]  K. Node,et al.  Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial , 2021, Cardiovascular Diabetology.

[6]  L. Køber,et al.  Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). , 2021, Circulation.

[7]  E. Abel.  Insulin Signaling In the Heart. , 2021, American journal of physiology. Endocrinology and metabolism.

[8]  C. Napoli,et al.  Evidence for human diabetic cardiomyopathy , 2021, Acta Diabetologica.

[9]  K. Node,et al.  Letter by Tanaka and Node Regarding Article, "Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study". , 2021, Circulation. Cardiovascular quality and outcomes.

[10]  L. Køber,et al.  Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. , 2020, The lancet. Diabetes & endocrinology.

[11]  L. Køber,et al.  Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. , 2020, Journal of the American College of Cardiology.

[12]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[13]  L. Maier,et al.  Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes , 2020, ESC heart failure.

[14]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[15]  B. Caramelli,et al.  Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR and restores euvolemia in nondiabetic rats with induced heart failure , 2020, bioRxiv.

[16]  J. Oyama,et al.  Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE) , 2020, ESC heart failure.

[17]  A. Banerjee,et al.  Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study , 2020, Diabetes, obesity & metabolism.

[18]  W. Ogawa,et al.  Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. , 2020, Endocrine journal.

[19]  E. Braunwald,et al.  Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[20]  Y. Hattori.  Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization , 2020, Heart Failure Reviews.

[21]  N. Kumashiro,et al.  Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR) , 2020, Cardiovascular diabetology.

[22]  Vanessa Souza-Mello,et al.  Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress , 2019, Molecular and Cellular Endocrinology.

[23]  S. Kaneko,et al.  Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet , 2019, BMJ Open Diabetes Research & Care.

[24]  H. Heerspink,et al.  Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[25]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[26]  S. Mudaliar,et al.  Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[27]  M. Packer.  Role of the sodium‐hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes , 2018, Diabetes, obesity & metabolism.

[28]  Yasushi Tanaka,et al.  Tofogliflozin decreases body fat mass and improves peripheral insulin resistance , 2018, Diabetes, obesity & metabolism.

[29]  R. Coronel,et al.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation , 2017, Diabetologia.

[30]  M. Packer.  Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure , 2017, Circulation.

[31]  S. Kaneko,et al.  SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice , 2017, EBioMedicine.

[32]  M. Jensen,et al.  How to Measure Adipose Tissue Insulin Sensitivity , 2017, The Journal of clinical endocrinology and metabolism.

[33]  K. Node,et al.  Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. , 2017, Journal of cardiology.

[34]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[35]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[36]  W. Shimizu,et al.  Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial , 2016, Cardiovascular Diabetology.

[37]  E. Abel,et al.  Insulin Signaling and Heart Failure. , 2016, Circulation research.

[38]  T. Kadowaki,et al.  Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. , 2016, Endocrinology.

[39]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[40]  Daniala L. Weir,et al.  Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients , 2013, Circulation. Heart failure.

[41]  I. Komuro,et al.  p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. , 2012, Cell metabolism.

[42]  G. Ferns,et al.  Selection of the appropriate method for the assessment of insulin resistance , 2011, BMC medical research methodology.

[43]  A. Vaag,et al.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.

[44]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[45]  M. Shimabukuro,et al.  Impaired Glucose Tolerance, but Not Impaired Fasting Glucose, Underlies Left Ventricular Diastolic Dysfunction , 2011, Diabetes Care.

[46]  C. Kahn,et al.  Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. , 2010, The Journal of clinical investigation.

[47]  R. DeFronzo.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 , 2010, Diabetologia.

[48]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[49]  E. Ingelsson,et al.  Insulin resistance and risk of congestive heart failure. , 2005, JAMA.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  L. Bouter,et al.  Insulin and risk of cardiovascular disease: a meta-analysis. , 1998, Circulation.

[52]  K. Yano,et al.  Hyperinsulinemia and cardiovascular disease in elderly men: the Honolulu Heart Program. , 1998, Arteriosclerosis, thrombosis, and vascular biology.